Disease | bronchopulmonary dysplasia |
Comorbidity | C0020538|hypertension |
Sentences | 11 |
PubMedID- 25231322 | Echocardiographic assessment of pulmonary hypertension in infants with bronchopulmonary dysplasia: systematic review of literature and a proposed algorithm for assessment. |
PubMedID- 23788443 | Pulmonary hypertension in bronchopulmonary dysplasia: clinical findings, cardiovascular anomalies and outcomes. |
PubMedID- 24616323 | Pulmonary hypertension in bronchopulmonary dysplasia. |
PubMedID- 25787794 | Pulmonary arterial hypertension associated with bronchopulmonary dysplasia and congenital heart disease in preterm infants. |
PubMedID- 22311993 | Objectives: pulmonary hypertension is associated with bronchopulmonary dysplasia in extremely low birth weight (elbw) infants and contributes to morbidity and mortality. |
PubMedID- 21189939 | Pulmonary hypertension in infants with bronchopulmonary dysplasia. |
PubMedID- 22848815 | More recently pulmonary hypertension (ph) associated with bronchopulmonary dysplasia (bpd) has been identified as a significant cause of mortality among bpd patients [1, 2]. |
PubMedID- 24350610 | Significance: abnormal lung development in the perinatal period can result in severe neonatal complications, including persistent pulmonary hypertension (ph) of the newborn and bronchopulmonary dysplasia. |
PubMedID- 24866752 | Sildenafil, a phospohodiesterase-5 inhibitor, is widely used to treat pulmonary hypertension in infants with bronchopulmonary dysplasia despite a lack of evidence to support either safety or efficacy and us fda advice against its use. |
PubMedID- 25824807 | Sildenafil for the treatment of pulmonary arterial hypertension in infants with bronchopulmonary dysplasia. |
PubMedID- 23582967 | Pulmonary hypertension in bronchopulmonary dysplasia. |
Page: 1